Dimerix Ltd (ASX: DXB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Dimerix Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$159.38 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
549.59 million
Earnings per share
-0.029
Dividend per share
N/A
Year To Date Return
39.02%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Dimerix Ltd (ASX: DXB)
Latest News
Share Market News
Why the Dimerix (ASX:DXB) share price is up today
Share Market News
Why the Dimerix (ASX:DXB) share price is surging 6% higher today
Share Market News
Why the Dimerix (ASX:DXB) share price has plunged 63% today
Growth Shares
3 ASX shares that could make you rich
Speculative
Dimerix share price doubles after being included in global COVID-19 study
❮2
DXB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Dimerix Ltd
A clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix's lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200
DXB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Apr 2024 | $0.29 | $0.01 | 3.51% | 1,433,489 | $0.29 | $0.30 | $0.29 |
| 17 Apr 2024 | $0.29 | $-0.01 | -3.45% | 1,869,448 | $0.29 | $0.29 | $0.28 |
| 16 Apr 2024 | $0.29 | $-0.01 | -3.33% | 3,079,409 | $0.30 | $0.30 | $0.29 |
| 15 Apr 2024 | $0.30 | $-0.02 | -6.35% | 2,352,923 | $0.31 | $0.31 | $0.30 |
| 12 Apr 2024 | $0.32 | $0.02 | 6.78% | 3,430,366 | $0.30 | $0.32 | $0.30 |
| 11 Apr 2024 | $0.30 | $-0.01 | -3.28% | 1,557,719 | $0.30 | $0.30 | $0.29 |
| 10 Apr 2024 | $0.31 | $0.02 | 7.02% | 2,998,353 | $0.29 | $0.31 | $0.29 |
| 09 Apr 2024 | $0.29 | $-0.01 | -3.39% | 1,938,332 | $0.30 | $0.30 | $0.29 |
| 08 Apr 2024 | $0.30 | $0.02 | 7.27% | 2,191,040 | $0.28 | $0.30 | $0.28 |
| 05 Apr 2024 | $0.28 | $-0.01 | -3.51% | 2,093,963 | $0.28 | $0.29 | $0.28 |
| 04 Apr 2024 | $0.29 | $0.00 | 0.00% | 1,343,381 | $0.29 | $0.29 | $0.28 |
| 03 Apr 2024 | $0.29 | $-0.01 | -3.45% | 1,118,300 | $0.29 | $0.29 | $0.29 |
| 02 Apr 2024 | $0.29 | $-0.01 | -3.33% | 2,613,803 | $0.30 | $0.30 | $0.29 |
| 28 Mar 2024 | $0.30 | $-0.01 | -3.28% | 2,683,913 | $0.31 | $0.31 | $0.30 |
| 27 Mar 2024 | $0.31 | $0.01 | 3.39% | 4,322,774 | $0.29 | $0.32 | $0.29 |
| 26 Mar 2024 | $0.30 | $-0.01 | -3.33% | 4,031,983 | $0.30 | $0.30 | $0.29 |
| 25 Mar 2024 | $0.30 | $-0.02 | -6.25% | 6,132,192 | $0.32 | $0.33 | $0.30 |
| 22 Mar 2024 | $0.32 | $-0.02 | -5.88% | 3,700,270 | $0.33 | $0.34 | $0.32 |
| 21 Mar 2024 | $0.34 | $0.02 | 6.15% | 9,035,148 | $0.32 | $0.35 | $0.32 |
| 20 Mar 2024 | $0.33 | $0.01 | 3.17% | 6,617,124 | $0.31 | $0.34 | $0.31 |
| 19 Mar 2024 | $0.32 | $0.01 | 3.23% | 2,720,219 | $0.31 | $0.32 | $0.31 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Mar 2024 | Nina Webster | Buy | 33,000 | $10,230 |
On-market trade.
|
| 26 Mar 2024 | Sonia Poli | Exercise | 12,501 | $1,575 |
Exercise of options.
|
| 26 Mar 2024 | Sonia Poli | Issued | 12,501 | $1,575 |
Exercise of options.
|
| 19 Mar 2024 | Nina Webster | Issued | 93,750 | $11,812 |
Exercise of options.
|
| 19 Mar 2024 | Nina Webster | Exercise | 93,750 | $11,812 |
Exercise of options.
|
| 01 Dec 2023 | Nina Webster | Issued | 2,052,956 | $282,675 |
Employee Share Ownership Plan. Black-Scholes valuation
|
| 30 Oct 2023 | Nina Webster | Expiry | 6,351,975 | $1,079,835 |
Options expired.
|
| 28 Jun 2023 | Nina Webster | Issued | 34,167 | $13,666 |
Rights issue.
|
| 28 Jun 2023 | Sonia Poli | Issued | 11,334 | $4,533 |
Rights issue.
|
| 05 Jun 2023 | Nina Webster | Issued | 187,500 | $15,000 |
Rights issue.
|
| 05 Jun 2023 | Nina Webster | Issued | 187,500 | $12,750 |
Rights issue.
|
| 05 Jun 2023 | Sonia Poli | Issued | 125,000 | $10,000 |
Rights issue.
|
| 05 Jun 2023 | Sonia Poli | Issued | 125,002 | $8,500 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Mark P Diamond | Non-Executive Director | Dec 2023 |
--
|
| Mr Hugh Alsop | Non-Executive Director | May 2017 |
Mr Alsop is an accomplished and commercially focused executive with experience in international business development, partnering, drug development and leadership of scientific teams. Hugh is currently CEO of Kinoxis Therapeutics, a private company developing novel therapeutics for substance use disorders and other neurological conditions. Prior to Kinoxis, Hugh was CEO of venture-backed private company Hatchtech, where he was responsible for several drug development programs for the international markets. Hugh is also a non Executive Director of private companies Servatus Ltd, Eflare Corporation Pty Ltd, Avalyn Australia Pty Ltd, AnaptysBio Pty Ltd and Lassen Therapeutics1 Pty Ltd.
|
| Ms Nina Webster | Chief Executive OfficerManaging Director | Aug 2018 |
Ms Webster has experience in the pharmaceutical industry, with leadership roles across strategy, commercialisation, intellectual property, scientific and operational aspects of product development.Nina worked in large Pharma, Wyeth Pharmaceuticals (UK). Nina is also a Non-Executive Director of Linear Clinical Research Limited and SYNthesis BioVentures Pty Ltd.
|
| Dr Sonia Maria Poli | Non-Executive Director | Jul 2015 |
Ms Poli is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. Sonia is currently serving as advisor for several late stage drug development projects approaching market authorization. Sonia was formerly Executive Manager at AC Immune,Nasdaq listed company, and Chief Scientific Officer at Minoryx and Addex Therapeutics and she has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche.
|
| Mr Clinton Snow | Non-Executive Director | May 2023 |
Mr Snow has 20 years experience as a technology leader with a focus in engineering management, project delivery, risk management and assurance. Clinton is providing advisory services to a family office with multiple Australian biotech investments.
|
| Mr Hamish George | Chief Financial OfficerCompany Secretary | May 2019 |
-
|
| Hamish George | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Peter Fletcher Meurs | 35,572,412 | 9.08% |
| Skiptan Pty Ltd <P&M Meurs Family A/C> | 29,357,028 | 7.50% |
| Freedom Trader Pty Ltd | 9,375,152 | 2.39% |
| Bavaria Bay Pty Ltd | 7,316,992 | 1.87% |
| Yodambao Pty Ltd | 6,362,603 | 1.62% |
| Mrs Melinda Jane Coates & Mr Andrew Joseph Coates | 5,000,000 | 1.28% |
| Mr Philip Robert Scott | 4,425,000 | 1.13% |
| Mrs Julie Maree Scott | 4,425,000 | 1.13% |
| Mr Andrew Joseph Coates & Mrs Melinda Jane Coates | 4,311,500 | 1.10% |
| Mr Richard Stanley De Ravin | 4,200,000 | 1.07% |
| Tamer Yigit Property Group Pty Ltd | 3,870,000 | 0.99% |
| Mr Taylor Nicholas Green | 3,500,000 | 0.89% |
| Mr Anthony Mark Van Der Steeg | 3,090,519 | 0.79% |
| Limnos 34 Pty Ltd | 3,000,728 | 0.77% |
| Mrs Gwen Murray Pfleger | 2,807,984 | 0.72% |
| Rubi Holdings Pty Ltd | 2,500,000 | 0.64% |
| Coates Family Office Pty Ltd | 2,300,000 | 0.59% |
| Toroha Pty Ltd | 2,137,753 | 0.55% |
| Moore Family Nominees Pty Ltd | 2,000,000 | 0.51% |
| Solequest Pty Ltd | 2,000,000 | 0.51% |
| Citicorp Nominees Pty Limited | 1,953,707 | 0.50% |
| Jampaso Pty Ltd | 1,778,742 | 0.45% |
